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Previous work showed that retaining residual ovarian tissue protects young mice from accelerated bone loss following ovarian
failure. The present study was designed to determine whether this protection is also present in aged animals. Aged (9–12 months)
C57BL/6Hsd female mice were divided into: CON (vehicle), VCD (160mg/kg; 15d), or OVX (ovariectomized). Lumbar BMD was
monitoredbyDXAandμCTusedtoassessvertebralmicroarchitecture.BMDwasnotdiﬀerentbetweenVCDandCONatanytime
point but was lower (P<. 05) than baseline, starting 1 month after ovarian failure in VCD and OVX mice. Following μCT analysis
there were no diﬀerences between CON and VCD, but OVX mice had lower bone volume fraction, trabecular thickness, and a
trend for decreased connectivity density. These ﬁndings provide evidence that retention of residual ovarian tissue may protect
aged follicle-depleted mice from accelerated bone loss to a lesser extent than that observed in young mice.
1.Introduction
Life expectancy has increased such that today’s women live
on average a third of their lives in a postmenopausal stage.
studying menopause has become of great importance due to
its association with serious health risks such as osteoporosis
[1], cardiovascular disease [2], ovarian cancer [3], and
Alzheimer’s disease [4]. Because women are expected to
live a third of their lives after menopause, this translates
to approximately three decades of increased risk for such
disorders.
Inwomen,17β-estradiol(E2)promotesosteoblastprolif-
eration and collagen synthesis, blunts the eﬀects of parathy-
roid hormone (PTH) to resorb calcium from bone, and
directs 1,25 dihydroxy-vitamin D (1,25(OH)2D3) action to
the intestines for calcium and phosphate absorption [5].
A c c e l e r a t e dl o s so fb o n em i n e r a ld e n s i t y( B M D )h a sb e e n
associated with the loss of estrogen following menopause
[6, 7]. Signiﬁcant loss of bone mass leads to osteoporosis.
Osteoporosis is a disease characterized by deterioration
of bone tissue that leads to bone fragility and increased
susceptibility to fractures [8, 9]. There are an estimated
10 million cases of osteoporosis in the United States, of
which 80% are women. It is estimated that by the year
2025, annual costs associated with osteoporotic fractures
will rise to $25.3 billion [10]. Therefore, studies aimed at
understanding the biology of postmenopausal osteoporosis
are of extreme importance.
The most common and widely accepted animal model
for studying the eﬀects of ovarian failure on bone physiology
istheovariectomized(OVX)rodent.However,onedrawback
to the OVX animal is that it cannot reproduce the eﬀects
of natural onset of menopause since removal of ovarian
function is abrupt. The perimenopause may be associated
with altered hormone levels and declines in bone mass
[11]. Because the OVX animal cannot mimic that process,2 Journal of Osteoporosis
an animal model capable of reproducing both peri- and
postmenopause could provide better information regarding
postmenopausal osteoporosis.
An ovary-intact mouse model of menopause has been
developed using the chemical 4-vinylcyclohexene diepoxide
(VCD). VCD has been shown to selectively destroy the
smallest preantral (primordial and primary) follicles in
ovaries of mice and rats by accelerating the natural process
of follicular atresia [12–15]. Because VCD does not target
larger follicles, the animal continues to ovulate normally
until no more follicles are available for recruitment. Thus,
ovarian follicular depletion in the VCD-treated mouse
(VCD mouse) is gradual. As with women undergoing
perimenopause, VCD-treated mice show increased levels of
FSH [16], declining levels of estrogen, and irregular estrous
cycles [17] as they become follicle-depleted. Additionally,
following ovarian failure residual ovarian tissue is retained.
Therefore, the VCD-treated mouse is relevant for studies
related to both perimenopausal and postmenopausal stages
[18].
There has been an ongoing controversy as to whether
residual ovarian tissue in postmenopausal women is
steroidogenic [19–22]. This is important to resolve because,
in the face of declining 17 β-estradiol, androgens produced
by residual ovarian tissue could impact postmenopausal
health in a negative or positive manner. Previous studies
reported that dispersed cells collected from residual ovarian
tissue in VCD-treated mice were capable of producing
androstenedioneinvitro[16]andthatresidualovariantissue
expresses the enzymatic machinery necessary to synthesize
androgens de novo [23]. Further, a previous paper has
demonstrated that retaining residual ovarian tissue in young
VCD-treatedfollicle-depletedmiceprotectsthemfromaccel-
erated bone loss following ovarian failure [24]. Therefore,
the purpose of this study was to determine in aged follicle-
depleted mice whether retaining residual ovarian tissue also
inﬂuences bone loss relative to ovariectomized and normally
cycling animals.
2.MaterialsandMethods
2.1. Animals. Cycling female C57BL/6Hsd mice (24 retired
breeders; aged 9–12 months) were purchased from Harlan
Sprague-Dawley, Inc. (Indianapolis, IN). Upon arrival, ani-
mals were housed in polycarbonate plastic cages, kept at
22 ± 2◦C on 12L: 12D cycles and fed ad libitum. All animals
were allowed to acclimate to the animal facilities for 1 week
before the start of the experiment. Each animal was assigned
randomly to one of three groups: (1) vehicle control, (2)
VCD, or (3) ovariectomy. All experiments and methods
were approved by the University of Arizona Institutional
Animal Care and Use Committee (IACUC) and conformed
to the Guide for the Care and Use of Experimental
Animals.
2.2. Induction of Ovarian Failure (VCD Dosing). Animals
in the VCD group received VCD (160mg/kg/d; i.p.; Sigma-
Aldrich, St. Louis, MO, n = 8 mice) dissolved in sesame oil
(vehicle) to induce ovarian failure. Animals in the control
group (CON) received sesame oil only (i.p; Sigma-Aldrich;
n = 8 mice). Mice were weighed and dosed daily for 15
days and estrous cyclicity was monitored by daily vaginal
cytology in both groups. Ovarian failure was assigned when
mice showed ≥10 days of persistent diestrus [17]. On-
going estrous cyclicity was conﬁrmed in the vehicle-treated
controls (CON), and only VCD-treated mice underwent
ovarian failure.
2.3.SurgicalRemovalofOvaries(Ovariectomy). Tomatchthe
age at the onset ovarian failure and therefore the duration of
exposure to estrogen deﬁciency, ovariectomy was performed
in a separate group of untreated mice at the average time
when mice in the VCD group experienced ovarian failure
(day 35 after the onset of dosing in CON and VCD mice).
Animals (n = 8) were placed under Ketamine/Xylazine
anesthesia (“Ketaject”, Phoenix Pharmaceutical, Inc, St.
Joseph, MO, USA; “AnaSed” from Lloyd Pharmaceuticals,
Inc., Shenandoah, IA, USA), and the right and left ﬂanks
were shaved, and skin was cleaned with Povidone-iodine
and 70% ethanol. Incisions were made through the skin,
fascia, and abdominal wall, and the ovaries were identiﬁed
and externalized. A ligature was placed at the ovary/oviduct
boundary before each ovary was removed. The muscle
wall and skin were closed using 6-0 and 3-0 braided silk
suture, respectively. Tissumend II surgical glue (Veterinary
Products Laboratories, Phoenix, AZ, USA) was applied over
the incision to prevent reopening of the wound.
2.4. Tissue Collection. Animals were euthanized by CO2
inhalation followed by cervical dislocation on day 181 after
the beginning of experiment. Skeletons were ﬁxed in 10%
neutral buﬀered formalin for 48h and transferred to 70%
ethanol for 24h.
2.5. Bone Mineral Density (BMD) Measurements. Lum-
bar BMD was determined in vivo by Dual-energy X-ray
Absorptiometry (DXA) using a PIXImus absorptiometer
(GE Lunar, Madison, WI). After performing quality con-
trol measurements, animals were placed under anesthesia
(Ketamine/Xylazine mix) and scanned. For each DXA scan,
the region of interest (ROI) was manually set to include
lumbar vertebrae 2–4.
2.6. Micrcomputed Tomography (μCT). Vertebrae were eval-
uated using a desktop μCT imaging system (μCT40; Scanco
Medical AG, Bassersdorf, Switzerland) equipped with a
10-mm focal spot microfocus X-ray tube and images
acquired with a 12μm isotropic voxel size, as previously
described [25]. Morphometric variables describing bone
microstructure were computed using direct 3D methods,
including bone volume fraction (BV/TV, %), trabecular
number (Tb.N, mm−1), trabecular thickness (Tb.Th, μm),
trabecular separation (Tb.Sp, μm), connectivity density
(ConnD, mm−3), and the structure model index (SMI), a
measure of the plate- versus-rod-like nature of the trabecular
structure.Journal of Osteoporosis 3
2.7. Statistical Analysis. Data were compared using ANOVA
followed by a Fischer’s PLSD (Protected Least Signiﬁcant
Diﬀerence) post hoc test. Statistical tests were conducted
using StatView for Windows (version 5.0, SAS Institute, Inc.,
Cary, NC) with the signiﬁcance level set at P<. 05 for all
tests. An observation was considered a trend with P ≤ .09
but >. 05.
3. Results
3.1. VCD-Induced Ovarian Failure. Retired breeders (9–12
monthsold)weredoseddailywithVCDtoinducepremature
ovarianfailure.Theaveragedayofovarianfailurewasd34.8±
1.3 (range: d31–39) after the onset of dosing. Thus, the
ovaries from OVX mice were removed on d35 after the onset
of dosing to match ovarian failure in VCD-treated mice.
Estrous cyclicity was determined in vehicle control-treated
animals to conﬁrm ovarian cyclicity. Throughout the month
precedingtheendofthestudy(d151−d181),cyclingcontrols
had estrous cycles of 5.08±0.34 days (range: 3–7 days; estrus
to estrus).
3.2. Changes in Bone Mineral Density in Mice following
Ovarian Failure. Lumbar bone mineral density (BMD) of
aged VCD-treated and ovariectomized (OVX) mice was
monitored by DXA and compared to that in age-matched
cycling controls (Figure 1). Lumbar BMD was not diﬀerent
between VCD-treated animals and age-matched cycling
controls at any of the measured time points. However,
relativetocyclingandVCD-treatedanimals,OVXhadhigher
(P<. 05) lumbar BMD at the two time points preceding
ovarian failure, but was not diﬀerent from the other groups
at any other time point. In order to obtain information
regarding the amount of bone density gain or loss within
eachgroup,alldatawascomparedtotheirrespectivebaseline
BMD (Figure 1;C O N :0 .051 ± 0.002g/cm3;V C D :0 .051 ±
0.001g/cm3;O V X :0 .052 ± 0.001g/cm3). As expected for
animals without ovarian failure, lumbar BMD in cycling
control mice did not change (P>. 05) over time until the
endofthestudy(range:0.051±0.002to0.048±0.003g/cm3).
However, both VCD-treated and OVX animals experienced a
decline (P<. 05) from baseline in BMD starting on d59 (age:
∼11–14months; ∼1monthafterovarianfailureorsurgeryin
VCD and OVX mice) and continuing to the end of the study
(VCD: 0.051±0.001 to 0.043±0.004g/cm3, 16% loss; OVX:
0.052 ±0.001 to 0.044 ±0.002g/cm3, 14.7% loss).
3.3. Evaluation of Trabecular Bone Microarchitecture in Aged
Mice. Trabecular bone microarchitecture of the ﬁfth lumbar
vertebral body was assessed by μCT after sacriﬁce on d181,
after the onset of dosing (age: 18.8 months; Figure 2). There
were no diﬀerences in any of the variables measured between
cycling controls and VCD-treated mice (P>. 05, Figure 2).
However, OVX mice had lower (P<. 05) BV/TV% and TbTh
and trends for decreased ConnD (P = .09) and increased
SMI when compared to the cycling control group (Figure 2).
In addition, OVX mice had lower (P<. 05) TbTh and a
t r e n df o rd e c r e a s e dC o n n D( P = .06) compared to VCD-
treated mice. Two-dimensional frontal planar images of the
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Figure 1: Temporal changes in lumbar BMD in aged mice. Aged
C57BL/6Hsd female mice (9–12 months old) were dosed daily for
15 days with sesame oil (vehicle; CON) or VCD (160 mg/kg). An
additional group of age-matched animals was not dosed but rather
underwent bilateral ovariectomy (OVX) on d35 after the onset of
dosing (matching ovarian failure in VCD-treated mice). BMD was
determinedusingDXAasdescribedinSection2.Dataarepresented
as percentage from baseline BMD ± SEM (n = 5–8). (#) and ($)
indicate P<. 05 from baseline BMD for VCD and OVX groups,
respectively, and (&) indicates P<. 05 versus OVX. The dashed
arrow indicates onset of ovarian failure in VCD-treated mice, and
thedashedboxindicatesBMDvaluesmeasuredafterovarianfailure
had occurred.
vertebral bodies of ovariectomized animals showed obvious
loss of integrity when compared to images from vertebrae of
cycling control-treated and VCD-treated animals (Figure 3).
4. Discussion
This study was designed to determine whether retaining
residual ovarian tissue inﬂuences the rate or extent of
ovarian failure-induced bone loss in aged, follicle-depleted
mice. In order to investigate the eﬀect of ovarian failure
on bone integrity, lumbar BMD of aged VCD-treated and
ovariectomized mice was evaluated by DXA and μCT and
compared to that in age-matched cycling animals. There
were no diﬀerences in lumbar BMD between VCD-treated
and cycling control animals throughout the study. Lumbar
BMD of cycling controls did not diﬀer over time until
the end of the study (age: 17.1 months). In comparison,
within 1 month from ovarian failure, both VCD-treated
and OVX mice experienced a decline in bone mineral
density that remained stable until the end of the study.
Trabecular bone microarchitecture, assessed by μCT did not
diﬀer between aged VCD-treated mice and age-matched
cyclinganimals.However,OVXanimalsshoweddeteriorated
trabecular architecture relative to both age-matched cycling
controls and VCD-treated mice. In particular, OVX mice
had decreased bone volume fraction and trabecular thick-
ness, along with trends for decreased connectivity density
and a more rod-like architecture. Compared to trabecular4 Journal of Osteoporosis
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Figure 2: Trabecular microarchitecture in aged VCD-treated and ovariectomized mice. Aged C57BL/6Hsd female mice (9–12 months old)
were dosed daily for 15 days with sesame oil (vehicle; CON) or VCD (160mg/kg) or were ovariectomized on d35 after the start of the
experiment. Trabecular bone microarchitecture of the ﬁfth vertebral body was assessed by μCT on samples collected at 5-month postovarian
failure (age: 18.8 months; d181) as described in Section 2. Data are represented as mean ± SEM (n = 4–6). Signiﬁcance was set at P<. 05.
The following variables were measured: bone volume fraction (BV/TV%), trabecular thickness (TbTh, μm), trabecular separation (TbSp,
μm), trabecular number (TbN, 1/mm), connectivity density (ConnD, 1/mm3), and structure model index (SMI). (∗) indicates P<. 05
versus CON; (#) indicates P<. 05 versus VCD. Trends are represented by bars indicating the corresponding P-value.
1mm
(a)
1mm
(b)
1mm
(c)
Figure 3: Representative two-dimensional frontal planar μCT images showing changes in bone integrity of the ﬁfth vertebral body of VCD-
treated and ovariectomized mice. Aged C57BL/6Hsd female mice (9–12 months old) were dosed daily for 15 days with sesame oil (vehicle;
CON) or VCD (160mg/kg) or ovariectomized on d35 after the start of the experiment. Trabecular bone microarchitecture of the ﬁfth
vertebral body was assessed by μCT on samples collected at 5-month postovarian failure (age: 18.8 months; d181) as described in Section 2.
Shownarerepresentativeimagesofvertebralbodiesexcisedfrom:(a)acyclingcontrol-treated,(b)aVCD-treated,and(c)anovariectomized
animal. The scale bar represents 1.0mm in all images.Journal of Osteoporosis 5
microarchitecture values reported in a previous study [24],
the 18.8-month-old cycling controls in the present study
had 51.4% lower bone volume, 45.1% lower trabecular
number, 84.8% greater trabecular separation, and 74.4%
lower connectivity density than the 3-month-old mice of the
same strain. Therefore, the lack of diﬀerences in trabecular
microarchitecture may be explained by age-dependent loss
of bone integrity in the cycling control group.
A previous study conducted in young mice supports the
hypothesis that retaining residual ovarian tissue can aﬀord
protection against accelerated bone loss following ovarian
failure [24]. In that study, young OVX mice showed reduced
lumbar BMD when compared to cycling animals 1 month
after ovariectomy while BMD from VCD-treated, follicle-
depletedanimalsdidnotdiﬀeruntilapproximately3months
after VCD-induced ovarian failure. Results from that study
also showed that despite observing signiﬁcant trabecular
deterioration in both mouse models of ovarian failure,
changes in the OVX group were more dramatic than those
observed in VCD-treated mice. One proposed mechanism
for this protection is the production of androgens by
residual ovarian tissue. Androgens derived from residual
steroidogenesis may act directly on androgen receptors
previously identiﬁed in bone tissue [26]o rb ec o n v e r t e dt o
estrogens by aromatase expressed in bone [27–30]b e f o r e
acting on bone cells to protect against accelerated bone
loss. Increased production of androstenedione has been
shown in young VCD-treated, follicle-depleted mice [16,
23]. Also, young VCD-treated mice have been shown to
have levels of androstenedione that are similar to those
in cycling mice, but higher than those observed in age-
matched OVX mice [24]. However, the present DXA data
using aged animals suggests that this beneﬁt may decrease
with advancing age. Previous work showed that circulating
androstenedione declines with age in cycling vehicle-treated
mice[23].Thisdecline,althoughnotcompletelyunderstood,
could be due to a decline in residual ovarian function as it
has also been observed in aging cycling women [31]a sw e l l
as in older postmenopausal women [32, 33]. A decline in
residual ovarian function and circulating androstenedione
may explain the diminished protection against bone loss
observed in aged, follicle-depleted mice in the present
experiment compared to that previously observed in young,
follicle-depleted mice.
5. Conclusion
Previous studies have demonstrated that the presence
of steroidogenically active residual ovarian tissue (versus
removal by OVX) seems to play a beneﬁcial role by retarding
bone loss following ovarian failure in young mice [24].
Surprisingly, this protection was not as obvious in the
present study, in which aged VCD and OVX animals had
similar progression to signiﬁcant bone loss when BMD
was monitored by DXA. No diﬀerences in trabecular bone
architecture were identiﬁed between aged VCD-treated and
cycling control mice, suggesting that cycling controls had
already undergone age-dependent loss of bone integrity at
the time of measurement (age: 18.8 months). However, there
were signiﬁcant detrimental eﬀects of ovarian failure on
trabecular bone of OVX animals compared to cycling and
VCD-treatedmice.Therefore,theseobservationssuggestthat
retaining residual ovarian tissue is less protective in aged
follicle-depleted mice than in young. These ﬁndings further
supporttheVCD-treatedmouseasausefulmodel forstudies
related to menopause and osteoporosis.
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